Kanabé is pleased to announce we have signed a letter of intent (LOI) with Abattis Bioceuticals, a cannabis downstream service provider and biotechnology company. Abattis will support us in further developing our formulations, providing cannabinoids, analytical and regulatory testing, as well as manufacturing services. This LOI will be the basis for a Definitive Agreement in which we will leverage the strategic partnership to support our expansion plans.
Kanabé’s product line of topicals, sublinguals, and capsules will focus on the adult-use market utilizing Abattis’ proprietary extraction technology, resulting in premium products with the latest innovation.
“Kanabé believes this partnership will enhance our formulations with access to Abattis’s full range of services and industry leading technologies resulting in premium quality products. Additionally, Kanabé is working to secure various distribution agreements for its line of health and wellness products with major retail chains, one of which has 100+ locations throughout various provinces. In addition to distribution agreements, Kanabé is poised and well situated to provide our products in distribution channels overseen by provincial commissions”, said Daniel Laferriere, CEO and founder of Kanabé Corp.
See the full press release from Abattis Bioceuticals here